Cargando…
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells
Chronic myeloid leukemia is a hematological cancer driven by the oncoprotein BCR-ABL1, and lifelong treatment with tyrosine kinase inhibitors extends patient survival to nearly the life expectancy of the general population. Despite advances in the development of more potent tyrosine kinase inhibitor...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080801/ https://www.ncbi.nlm.nih.gov/pubmed/33067577 http://dx.doi.org/10.1038/s12276-020-00515-5 |